News | Renal Denervation | October 11, 2016

New NIH Awards will Enhance Understanding of How Nerves Control Organ Function

NIH funds over $20 million in peripheral nervous system research

October 11, 2016 — Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system, in hopes of finding new ways to treat conditions such as asthma, diabetes and nausea. The new awards total more than $20 million in fiscal year 2016, and go to 27 multidisciplinary research teams through the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. The SPARC program plans to support awards totaling approximately $238M through fiscal year 2021, pending available funds.

This year’s awards encompass a wide range of projects intended to resolve existing knowledge gaps and technology limitations. In addition to treatment research, other projects focus on various organ systems, including heart, lung, stomach/intestine, colon, adipose tissue, spleen, bladder and pancreas.  

SPARC focuses on understanding peripheral nerves — nerves that connect the brain and spinal cord to the rest of the body — and how their electrical signals control internal organ function. Modulation of these control signals is a potentially powerful way to treat common conditions and diseases such as rheumatoid arthritis and heart failure. Methods and medical devices that modulate peripheral nerve activity are becoming available, but more research to fully understand how these therapies act on a target organ’s cells is needed. Such understanding could help to explain and resolve why a particular therapy may be effective in one individual, but not in another, thereby making these therapies effective for more people.

“SPARC fosters synergistic, multidisciplinary collaborations to advance this rapidly developing research area with high potential to enable new and improved treatments,” said James M. Anderson, M.D., Ph.D., director of the NIH Division of Program Coordination, Planning and Strategic Initiatives, which oversees the NIH Common Fund. “The insights gained from these cutting-edge, collaborative projects will accelerate development of methods and devices to treat diseases for which conventional therapies fall short.”

The 2016 awardees will work collectively as a consortium to address the goals and aims of SPARC. Biological projects will develop detailed anatomical and functional maps that illustrate how peripheral nerves control organ function, while technology development projects will create or improve tools to measure and manipulate nerve-organ interactions and isolate their functions. Additional projects include collaborations between private sector scientists and academic researchers, intended to expedite the development of new therapeutic strategies.

Going forward, the SPARC program will leverage expertise from many different sources — not only academic laboratories, but also independent inventors, start-ups, small and large businesses, and international organizations. Data and tools developed in the SPARC program will be shared through a central online resource. 

“The SPARC program invests in high-risk, goal-driven projects to discover the underlying mechanisms and pathways by which the peripheral nervous system controls internal organ function,” said SPARC Program Manager Gene Civillico, Ph.D. “This is achieved through a unique program management structure that allows SPARC to swiftly adopt new breakthroughs and emerging technologies, and nimbly incorporate ideas and expertise. These awards have the potential to catalyze next-generation neuromodulation therapies that could bring improved specificity for patients over both drug therapies and previous-generation devices.”

SPARC is funded through the NIH Common Fund and managed by the NIH Office of the Director, in partnership with the National Center for Advancing Translational Sciences, the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. The fiscal year 2016 funding will be issued via NIH Other Transaction and Cooperative Agreement award mechanisms.

For more information: www.nih.gov

Related Content

Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

News | EP Lab | June 02, 2021
June 2, 2021 — Implicity, a leader in remote patient monitoring software and cardiac data management solutions, annou
Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

News | EP Lab | May 25, 2021
May 25, 2021 — Acutus Medical Inc.
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Feature | EP Lab | May 16, 2021 | By Dave Fornell, Editor
May 16, 2020 — New data from in the ...
A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study

A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study

News | EP Lab | May 14, 2021
May 14, 2021 — The U.S.
Abbott Recalls Assurity and Endurity Pacemakers 
News | EP Lab | May 14, 2021
May 14, 2021 — Abbott is recalling a subset of Assurity and Endurity...
EP lab at the University of Colorado
News | EP Lab | May 12, 2021
May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablatio
The Bluegrass Vascular Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 

The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 

News | EP Lab | May 06, 2021
May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility
Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference. ICD depression
News | EP Lab | April 26, 2021
April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for
Former Vice President Mike Pence. Photo by Airman 1st Class Aubree Owens, 30th Space Wing Public Affairs

Photo by Airman 1st Class Aubree Owens, 30th Space Wing Public Affairs

News | EP Lab | April 19, 2021
April 19, 2021 — Former Vice President Mike Pence is recovering after having a...